antifungal agent

(redirected from amphotericin B)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to amphotericin B: liposomal amphotericin B
References in periodicals archive ?
The urgent challenge ahead for all involved in translating these guidelines into practice is to accelerate access to affordable treatment by supporting the registration and procurement of flucytosine and amphotericin B at affordable prices in all the countries where these drugs are needed.
Similar names of the two products: amphotericin B and lipid complex amphotericin B.
AmBisome consists of amphotericin B intercalated into a unilamellar bilayer vesicle consisting of phospholipids and cholesterol and measuring <100 run in diameter.
Outcomes in these patients were poor, with prolonged hospital admissions and considerable mortality despite prolonged treatment with amphotericin B.
To test the hypothesis that higher doses of liposomal amphotericin B might improve outcomes, a prospective, double-blind study was done to compare dosages of 10 mg/kg and 3 mg/kg daily in 201 highly immunocompromised patients.
Anaphylaxis has been reported with amphotericin B deoxycholate and other amphotericin B containing drugs, including AmBisome.
Amphotericin B is considered to be the principal drug for treating fungal infections and is often combined with other antifungal drugs such as Azoles (Sugar et al.
To meet the need for antifungal prophylaxis, a dry powder aerosol formulation of amphotericin B has been developed, and a multidose clinical study is underway, said Dr.
Liposomal amphotericin B is the drug of choice for treating Mediterranean VL.
Successful treatment of rhinocerebral mucormycosis by a combination of aggressive surgical debridement and the use of systemic liposomal amphotericin B and local therapy with nebulized amphotericin--A case report.
P boydii infections are difficult to treat due to amphotericin B resistance and frequent need for surgical resection.
These patients were either intolerant to (3 out of 24) or had failed treatment with conventional and/or liposomal amphotericin B (21 out of 24).
Nasdaq: BDSI) announced initial results of a Phase 1 study assessing the tolerability, safety, and pharmacokinetics of Bioral([TM]) Amphotericin B, BDSI's lead product candidate utilizing the company's Bioral drug delivery technology.
Switches were made because of intolerance or insufficient response in 24% of voriconazole patients, compared with 70% of amphotericin B patients (Clin.